NCT02626364View on ClinicalTrials.gov

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Recurrent/Refractory Glioblastoma
Interventions
DRUG

crenolanib

single-agent crenolanib at 100 mg PO TID

Trial Locations (1)

75243

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY